SecBot SecBot
PRESS-RELEASE ·Filed Mar 19, 2026

SABS

SAB Biotherapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Offering
Actionable Insight • Neutral

Monitor for future clinical trial updates on SAB-142, especially from the ongoing Phase 2b SAFEGUARD trial in type 1 diabetes. The capital raise extends the company's runway but increases share count significantly, watch for any changes in burn rate or development timelines.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.75
T+0 close · Mar 19, 2026 · via day close
Latest settled
+4.00%
T+60 · $3.90
Vs SPY
−10.42%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 20 $3.75entry
  2. T+1 · 8mo ago +4.80%α +3.70% · $3.93
  3. T+5 · 8mo ago +2.67%α +4.82% · $3.85
  4. T+20 · 7mo ago +2.93%α −6.39% · $3.86
  5. T+60 · 5mo ago +4.00%α −10.42% · $3.90
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

SAB Biotherapeutics (SABS) closed an underwritten public offering of 19,324,677 shares at $3.85 per share and pre-funded warrants for 2,753,246 shares at $3.8499 per warrant, raising approximately $85 million in gross proceeds. The company plans to use the funds to advance its lead candidate, SAB-142, through clinical trials for type 1 diabetes and for general corporate purposes. An additional 3,311,688-share over-allotment option remains open for 30 days.

Key Financial Metrics

Deal Value
$85.0M

Key Facts

  • SAB Biotherapeutics raised $85 million in gross proceeds through a public offering.
  • Offering included 19,324,677 common shares at $3.85 and pre-funded warrants for 2,753,246 shares at $3.8499.
  • Proceeds will fund clinical development of SAB-142 for type 1 diabetes, manufacturing, regulatory activities, and general corporate use.
  • Underwriters have a 30-day option to purchase up to 3,311,688 additional shares.
  • Jefferies, UBS, Citigroup, and Barclays acted as joint book-runners.

Financial Impact

$85 million gross proceeds, with potential for additional $12.7 million if over-allotment is exercised (3,311,688 shares × $3.85)

dilutioncashequity

Risk Factors

  • Significant shareholder dilution from issuance of over 22 million shares and warrants.
  • Clinical-stage risk: SAB-142 may fail in trials despite funding, leading to valuation decline.
  • Execution risk in advancing manufacturing and regulatory plans with new capital.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3259414

Track record

15 reports on SABS

Performance horizon

3 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +15.67% at T+20 after the Oct 13, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $3.00 Now $3.00 0.00% settles Dec 15
  2. Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $2.96 Now $3.00 +1.35% settles Dec 15
  3. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.00 Now $3.00 0.00% settles Dec 15
  4. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $2.94 Now $3.00 +2.04% settles Dec 4
  5. Oct 22, 202625d ago 25-NSE Neutral 2/10 Entry $2.84 Now $3.00 +5.63% settles Nov 20
  6. Oct 13, 20264w ago 8-K Bullish 6/10 Entry $2.68 to $3.07 Now $3.00 +11.94% ▲ +14.55% +18.16% vs SPY
  7. Oct 13, 20264w ago Press Release Bullish 5/10 Entry $2.68 to $3.10 Now $3.00 +11.94% ▲ +15.67% +19.34% vs SPY
  8. Jul 7, 202618w ago 8-K Bullish 4/10 Entry $3.90 to $3.79 Now $3.00 −23.08% ▼ −2.82% −4.15% vs SPY
  9. May 29, 202624w ago Press Release Neutral 3/10 Entry $3.60 to $3.90 Now $3.00 −16.67% ▲ +8.33% +10.13% vs SPY
  10. May 12, 202626w ago Press Release Bearish 7/10 Entry $3.62 to $3.31 Now $3.00 +17.13% ▲ +8.56% +6.84% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 19, 2026